Skip Navigation

DRUG RECORD

 

PIOGLITAZONE

OVERVIEW
Pioglitazone

 

Introduction

Pioglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes.  Pioglitazone has been linked to rare instances of acute liver injury.

 

Background

Pioglitazone (pye" oh gli' ta zone) is a thiazolidinedione thought to act by engagement of PPAR-γ receptors which induce multiple genes involved in glucose and fatty acid metabolism.  In clinical trials, pioglitazone was found to lower blood glucose and HbA1c levels and had additive effects with the sulfonylureas and metformin.  Pioglitazone was approved for use in the United States in 1999 and remains in wide use.  Current indications for pioglitazone are as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.  While the initial thiazolidinedione approved for use – troglitazone – was associated with high rates of serum aminotransferase elevations and multiple reports of severe liver injury and death from acute liver failure, pioglitazone has been associated with only rare instances of clinically apparent liver injury.  Pioglitazone is available in 15, 30 and 45 mg tablets generically and under the brand name Actos, and as a fixed combination with metformin (Actoplus Met and others) and with glimepiride (Duetact and others).  The recommended dosage is 15 to 45 mg once daily.  Pioglitazone is used as monotherapy as well as in combination with metformin, sulfonylureas or insulin.  Common side effects of pioglitazone include weight gain and edema.

 

Hepatotoxicity

In contrast to troglitazone, pioglitazone is not associated with an increased frequency of aminotransferase elevations during therapy.  In clinical trials, ALT elevations above 3 times the ULN occurred in only 0.26% of patients on pioglitazone, compared to 0.25% of placebo recipients (and 1.9% of troglitazone recipients in similar studies).  In addition, clinically apparent liver injury attributed to pioglitazone is very rare, fewer than a dozen cases having been described in the literature despite extensive use of this agent.  The liver injury usually arises between 1 and 6 months after starting therapy and all patterns of serum enzymes elevations have been described including hepatocellular, cholestatic and mixed.  Allergic phenomena are rare and autoantibodies have not been typically present.  Cases of acute liver failure attributed to pioglitazone have been reported, usually in association with a hepatocellular pattern of injury.  In most instances, recovery is complete within 2 to 3 months. 

 

Likelihood score: C (probable rare cause of clinically apparent liver injury).

 

Mechanism of Injury

The mechanism of liver injury due to pioglitazone is not known, but the general pattern and course differs somewhat from troglitazone and it is unlikely that the thiazolidinediones share a single mechanism for liver injury.

 

Outcome and Management

The liver injury from pioglitazone is usually reversed with stopping the medication.  Fatal instances of acute liver injury due to pioglitazone have been reported, but are rare.  Chronic liver disease and vanishing bile duct syndrome have not been associated with pioglitazone.  There exists at least some cross sensitivity to liver injury among the different thiazolidinediones, so that patients with pioglitazone hepatotoxicity should avoid use of rosiglitazone.

 

References to safety and hepatotoxicity of pioglitazone are given together with references to rosiglitazone and troglitazone in the Overview section on the Thiazolidinediones (updated June 2018).

 

Drug Class:  Antidiabetic Agents

 

Other Drugs in the Subclass, ThiazolidinedionesRosiglitazone, Troglitazone

 

Top of page


CASE REPORT
Pioglitazone

 

Case 1.  Acute liver injury after 6 months of pioglitazone therapy.
[Modified from: May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136: 449-52. PubMed Citation]

 

A 49 year old man with type 2 diabetes and poor control with glyburide and metformin was started on pioglitazone, which was slowly increased in dose.  Six months later he developed jaundice and was found to have elevations in serum aminotransferase and alkaline phosphatase levels (Table).  There was no fever, rash or eosinophilia.  He had had intermittent nausea and abdominal discomfort during pioglitazone therapy, but liver tests were previously normal.  He had no history of liver disease or risk factors for hepatitis.  Tests for hepatitis A, B and C were negative as were autoantibodies.  A liver biopsy showed cholestasis, portal inflammation and mild bile duct damage suggestive of mixed pattern of injury due to drug hepatotoxicity.  Pioglitazone was stopped on admission and he improved rapidly, all tests becoming normal within the following 6 weeks.

 

Key Points

Medication:Pioglitazone (15-45 mg daily for 6 months)
Pattern: Mixed (R=2.1)
Severity: 3+ (jaundice and hospitalization)
Latency: 6 months
Recovery: 6 weeks
Other medications: Metformin, glyburide, lisinopril and omeprazole chronically (continued during admission)

Laboratory Values

Time After Starting Time After Stopping ALT* (U/L) Alk P* (U/L) Bilirubin* (mg/dL) Other
Pre 30 30 0.6
6 months 0 218 312 5.7 Pioglitazone stopped
  3 days 487 617 10.4
  7 days 665 251 3.5 Liver biopsy: mixed injury
6.5 months 17 days 372 36 2.4
7 months 6 weeks 30 30 0.6
Normal Values <40 <116 < 1.2

* Values estimated from Figure 2 and converted to U/L and mg/dL.

 

Comment

Liver injury first arose after six months of therapy and was not detected early despite serum ALT monitoring.  The liver injury was self-limited and recovery was rapid.  Jaundice with a mixed pattern of serum aminotransferase elevations is typical of drug induced liver injury in general and occurs frequently, but not invariably, in cases of pioglitazone associated injury.

 

Top of page


PRODUCT INFORMATION
Pioglitazone

 

REPRESENTATIVE TRADE NAMES
Pioglitazone – Actos®

 

DRUG CLASS
Hypoglycemic Agents

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NUMBER MOLECULAR FORMULA STRUCTURE
Pioglitazone 112529-15-4 C19-H20-N2-O3-S.Cl-H Pioglitazone chemical structure

Top of page


OTHER REFERENCE LINKS
Pioglitazone

 

  1. PubMed logoRecent References on Pioglitazone

  2. Clinical Trials logoTrials on Pioglitazone

Top of page